CTSO - Pangali PEG Cytosorbents

Cytosorbents is expanding the presence of CytoSorb systems in intensive care units to capture the medical equipment market. The PEG fair value filter visualizes this process, where the value of 0.00 shows the latest figure. This trend relies on insurance coverage and clinical efficacy in treating sepsis, as well as the launch of the innovative Purifi system to combat cytokine storms.

Cytosorbents (CTSO) dominates the biomedical blood purification segment for combating sepsis in intensive care units. The growth-adjusted P/E trend reflects the balance between market value and profit expansion. This indicator divides the P/E ratio by the annual growth rate of net income. A value below one signals that the asset is undervalued relative to its scaling. This allows for the effective identification of undervalued high-tech companies for a long-term portfolio.